期刊文献+

AMPK与肺部炎症研究进展 被引量:15

Recent advances in the study of AMPK and inflammatory pulmonary disease
原文传递
导出
摘要 腺苷酸活化蛋白激酶(AMP-activated protein kinase,AMPK)是细胞的能量调节器,在维持机体能量代谢平衡中发挥重要作用。最近研究表明,AMPK能通过调节氧化应激、抗炎等途径减轻哮喘、慢性阻塞性肺病(chronic obstructive pulmonary disease,COPD)、肺部感染性疾病、肺纤维化的肺组织损伤。AMPK主要通过下游靶分子如沉默信息调节因子1(sirtuin1,SIRT1)、过氧化物酶体增殖物激活受体γ共激活因子-1α(peroxisome proliferator-activated receptorγcoactivator-1α,PGC-1α)、p53和FoxO转录因子3a(forkhead box O3a,FoxO3a)等抑制肺部炎症反应。因此,AMPK及其信号通路有望成为治疗肺部炎症疾病的药理学靶点。本文就AMPK与肺部炎症疾病的关系进行综述。 AMP-activated protein kinase (AMPK) is an important regulator of cellular energy homeostasis. Recent studies demonstrated that AMPK is a novel signaling molecule modulating inflammatory responses and oxidative stress which are involved in inflammatory pulmonary diseases, such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary infectious diseases and pulmonary fibrosis. AMPK attenuates inflammatory lung injury by phosphorylating its downstream targets, such as sirtuinl (SIRT1), peroxisome proliferatoractivated receptor γ coactivator-1α (PGC-1α), p53 and forkhead box O3a (FoxO3a). This review summarized the relationship between AMPK and the development of inflammatory pulmonary diseases.
作者 玄玲玲 侯琦
出处 《药学学报》 CAS CSCD 北大核心 2014年第8期1089-1096,共8页 Acta Pharmaceutica Sinica
基金 十二五综合大平台-药效学评价(37008) 医科院留学回国择优项目经费-哮喘炎症
关键词 AMPK 炎症 氧化应激 哮喘 COPD 肺部感染性疾病 肺纤维化 AMPK inflammation oxidative stress asthma COPD pulmonary infectious diseases pulmonaryfibrosis
  • 相关文献

参考文献1

二级参考文献39

  • 1Xiang Y, Yang HL. The physiological function of Sirtl and its correlation with tumor [J]. Mod Med Health, 2011, 27: 705-707. 被引量:1
  • 2Ogawa T, Wakai C, Saito T, et al. Distribution of the longevity gene product, SIRT1, in developing mouse organs [J].Congenit Anom (Kyoto), 2011, 51 : 70-79. 被引量:1
  • 3Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms [J]. Genes Dev, 1999, 13: 2570-2580. 被引量:1
  • 4Tissenbaum HA, Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans [J]. Nature, 2001, 410: 227-230. 被引量:1
  • 5Dryden SC, Nahhas FA, Nowak JE, et al. Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle [J]. Mol Cell Biol, 2003, 23: 3173-3185. 被引量:1
  • 6Starai VJ, Escalante-Semerena JC. Identification of the protein acetyltransferase (Pat) enzyme that acetylates acetyl-CoA synthetase in Salmonella enterica [J]. J Mol Biol, 2004, 340: 1005-1012. 被引量:1
  • 7Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance [J]. Annu Rev Pathol, 2010, 5: 253-295. 被引量:1
  • 8Motta MC, Divecha N, Lemieux M, et al. Mammalian SIRT 1 represses forkhead transcription factors [J]. Cell, 2004, 116: 551-563. 被引量:1
  • 9Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase [J]. Science, 2004, 303: 2011-2015. 被引量:1
  • 10Rajendrasozhan S, Yang SR, Kinnula VL, et al. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease [J]. Am J Respir Crit Care Med, 2008, 177: 861-870. 被引量:1

共引文献2

同被引文献139

  • 1张德平,庄谊,殷凯生.肌成纤维细胞凋亡与肺纤维化[J].国际呼吸杂志,2007,27(4):298-301. 被引量:7
  • 2赵勤,罗湘杭.骨代谢过程中脂联素的相关作用[J].中国组织工程研究与临床康复,2007,11(6):1127-1129. 被引量:5
  • 3Bando M, Hosono T, Mato N et al. Long-term effieary inhaled N- acelylcysteine patients with idoopathic pulmonary fibrosis [ J ]. In- tern Med ,2010,49 (21) :2289 - 2296. 被引量:1
  • 4Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ ALAT statement : idiopathic pulmonary fibrosis : evidence-based guidelines for diagnosis and management [ J ]. Am J Respir Crit Care Med ,2011 ;183 : 788 -824. 被引量:1
  • 5Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone Clinical Study Group in Japan. Pirfenidone in Idiopathic Pulmonary Fibrosis: A phase III clinical trial in Japan [ J]. Eur Respir,2010;35:821 - 829. 被引量:1
  • 6Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis ( CAPACITY ) : two randomised trials[ J]. Lancet, 2011 ;377:1760 - 1769. 被引量:1
  • 7Taniguchi H,Ebina M, Kondoh et al. Pirfenidone in idiopathic pul- monary fibrosis [ J ]. Eur Respir 2010,35 ( 4 ) : 821 - 829. 被引量:1
  • 8Luca Richeldi, Ulrich Costabel, Moises Selman, et al. Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis [ J ]. The New England Journal of Medicine,2011,365 (12) : 1079 - 1087. 被引量:1
  • 9Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis [ J ]. N Engl J Med, 2014,370:2071 - 2082. 被引量:1
  • 10Choe JY, Jung H J, Park KY, et. al. Antifibrotic effect ofthalidomide throuh inhibiting TGF-βinduced ERK1/2 pathways in bleomycin induced lung fibros is in mice [ J ]. Inf lamm Res, 2010,59 ( 3 ) : 177. 被引量:1

引证文献15

二级引证文献75

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部